An NCI-designated Comprehensive Cancer Center

Fouad R. Kandeel, M.D., Ph.D.

Professor and Chair, Department of Clinical Diabetes, Endocrinology & Metabolism
Clinical Expertise
Research Focus
  • Islet Cell Transplantation
  • Type 1 Diabetes
  • Sexual Dysfunction
Chair, Department of Translational Research and Cellular Therapeutics; Director, Islet Cell Transplant Program; Associate Director, Diabetes & Metabolism Research Institute; Arthur D. Riggs Distinguished Chair in Diabetes & Metabolism Research
Other Languages Spoken
  • Arabic

Clinical Teams

  • Thyroid and Parathyroid Cancers

Fouad Kandeel, M.D., Ph.D., is the principal investigator on the islet transplantation trial to determine the safety and efficacy of islet cell transplantation as a treatment for patients with type 1 diabetes. In addition, Dr. Kandeel has recently concluded a clinical project to identify genes related to the development of type 2 diabetes and cardiovascular disease in the Hispanic population. He also continues to oversee the Diabetes and Cardiovascular Risk Reduction Program, which he established several years ago at City of Hope. Due to his strong background in endocrine tumors and thyroid cancer, Dr. Kandeel participates in the development of the national guidelines for the management of neuroendocrine tumors and thyroid cancer.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

In The News

Faces of Diabetes Innovation Ep 4 Fouad Kandeel

An Expert's Voice
breakthroughs - diabetes research

COVID-19 and diabetes:
Important facts about the risks

Wanek Project - Fouad Kandeel

Super cells could help doctors detect cancer seven years sooner

City of Hope News

City of Hope’s Fouad R. Kandeel, M.D., Ph.D., appointed to new Arthur D. Riggs Distinguished Chair in Diabetes & Metabolism Research